“We’ve made tremendous progress in 2025, and July was a pivotal month for ProKidney (PROK) with the release of positive topline data from our Phase 2 REGEN-007 study and alignment with the FDA on the accelerated approval pathway for rilparencel using eGFR slope as the surrogate endpoint,” said Bruce Culleton, CEO of ProKidney. “We are now focused on maintaining enrollment momentum in the Phase 3 PROACT 1 study and preparing for a late-breaking submission of Phase 2 REGEN-007 data at ASN Kidney Week in November. Each step brings us closer to our goal of delivering a novel treatment option to patients with diabetes and advanced CKD, a population where there remains high unmet clinical need.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- Prokidney Corp options imply 15.7% move in share price post-earnings
- Prokidney Corp options imply 13.0% move in share price post-earnings
- Prokidney’s REACT Study: A Promising Step for Kidney Disease Treatment
- Largest borrow rate increases among liquid names
- ProKidney’s Hold Rating: Balancing FDA Alignment and Extended Approval Timeline